Wednesday, April 14, 2021

Warning: Young Women Experience Highest Blood Clot Risk from Leading Vaccines


Young women appear to be impacted the most from blood clots related to the AstraZeneca and Johnson & Johnson (J&J) coronavirus vaccines. The J&J vaccine has been authorized for emergency use in the U.S., but it’s use has been temporarily “paused” in the wake of this potential side effect.

It is important to note that all three coronavirus vaccines (J&J, Moderna and Pfizer) being used in America have been designated for Emergency Use Authorization (EUA). They have not been approved by the Food and Drug Administration. As clearly noted in their own press release:

The issuance of an EUA is different than an FDA approval (licensure) of a vaccine, in that a vaccine available under an EUA is not approved. 

After it was reported this week that the government is temporarily halting the use of the Johnson and Johnson vaccine, an article posted at the MIT Technology Review revealed that those who experienced blood clots were all women and “all between the ages of 18 and 48.”

Likewise, the AstraZeneca vaccine has only affected women under 60, as reported at RAIR Foundation USA. Notably, the head of the European Medicines Agency (EMA) Emer Cooke – a former lobbyist for the pharmaceutical company – downplayed the blood clots, stating that the benefits outweigh the risks.

The AstraZeneca vaccine is not authorized for emergency use in America. Last month, it was reported that the vaccine was suspended in eighteen countries.

Read more of RAIR’s coverage on coronavirus vaccines:

The post Warning: Young Women Experience Highest Blood Clot Risk from Leading Vaccines appeared first on RAIR.